Street Calls of the Week
NEW YORK - Applied DNA Sciences, Inc. (NASDAQ:BNBX), currently valued at approximately $5 million in market capitalization, has been named a B2i Digital Featured Company as it completes a strategic rebrand reflecting its pivot toward a yield-focused BNB digital asset treasury strategy. According to InvestingPro analysis, the company maintains a favorable cash position, holding more cash than debt on its balance sheet, though it’s currently experiencing rapid cash burn.
The biotechnology company, which recently changed its ticker from APDN to BNBX effective October 7, 2025, will maintain its nucleic acid production solutions business while implementing its digital asset management approach.
Applied DNA previously announced approximately $27 million in aggregate gross proceeds to implement its BNB treasury strategy, which will be managed under five-year agreements with Cypress LLC and Cypress Management LLC.
"Partnering with B2i Digital enables us to share our transformation and long-term vision with a much wider investor audience," said Clay Shorrock, CEO of Applied DNA Sciences, according to the company’s press release.
Through its LineaRx subsidiary, Applied DNA continues to commercialize its LineaDNA, LineaRNAP, and LineaIVT platforms for cell-free manufacturing of DNA and RNA for therapeutics and diagnostics.
As a B2i Digital Featured Company, Applied DNA will be introduced to retail and institutional investors across B2i Digital’s network, which includes over 1.4 million market participants across various social media platforms.
B2i Digital CEO David Shapiro stated that Applied DNA’s shift toward a BNB-centric digital asset treasury "underscores its commitment to innovation in corporate finance."
The company’s dual approach aims to generate yield and token accumulation within the Binance ecosystem while maintaining its operational technology expertise in nucleic acid production.
In other recent news, Applied DNA Sciences announced it has received a follow-on order valued at over $600,000 for its LineaDNA product. This marks the seventh order from a global manufacturer of in vitro diagnostics, which will use the product as a component in a cancer diagnostic test. Additionally, Applied DNA Sciences will change its ticker symbol on the Nasdaq Capital Market from "APDN" to "BNBX" starting October 7, 2025. The company stated that this change aligns with its strategic focus on a BNB-based treasury strategy aimed at enhancing capital efficiency and liquidity through decentralized finance protocols. Furthermore, Applied DNA Sciences plans to present its nucleic acid production solutions at two industry conferences in Boston. The company will showcase a poster titled "Fast-tracking mRNA Medicines: a synthetic DNA platform to optimize mRNA production" at the 4th Annual mRNA Process Development and CMC Summit. These developments reflect the company’s ongoing efforts to advance its product offerings and strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.